1030P Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Author:
B.J. Monk,T.J. Herzog,S. Triantos,S. Maul,G. Wang,M J Pontes Valero,T. McGowan,W.S. Shalaby,R.L. Coleman
Publication:
Annals of Oncology
Copyright © 2019 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.